EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

The 5‐Methylcytosine RNA Modification in Hepatitis B Virus‐Negative Hepatocellular Carcinoma: Insights From Long‐Read Nanopore Sequencing

Tianhan Sun iD, Liying Zhou, XiaoQing Li, Ryan Xiao, Gaoyuan Sun, Lili Zhang, Yifei Li, Wei Huang, Yayu Li, Lu Kuai, Xuanmei Luo, Hongyuan Cui and 1 more

Molecular Carcinogenesis · 2026

DOI: 10.1002/mc.70080 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2026. Written by Tianhan Sun and 12 co-authors. Institution: Department of General Surgery, Department of Hepato-bilio-pancreatic Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatri…. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, 5-Methylcytosine, Nanopore Sequencing. Cited 1 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Beijing Natural Science Foundation, CAMS Innovation Fund for Medical Sciences (CIFMS), National Key Research and Development Program of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

5‐Methylcytosine (m5C) RNA modification contributes to tumor initiation and progression. However, its transcriptome‐wide distribution patterns and biological implications in hepatitis B virus (HBV)‐negative hepatocellular carcinoma (HCC) remain poorly understood. Therefore, this study employs long‐read Nanopore direct RNA sequencing to systematically elucidate the mechanisms of m5C‐mediated epigenetic reprogramming in HBV‐negative HCC. Paired tumor and adjacent normal tissues from three HBV‐negative HCC patients were collected for Nanopore sequencing. Transcriptome‐wide m5C sites were profiled using the CHEUI tool, followed by a comprehensive comparison between tumor and adjacent normal tissue groups regarding the number of m5C sites, their genomic distribution characteristics, and the expression levels of m5C regulators. Finally, an integrated analysis of transcriptomic and methylation data was conducted to identify m5C‐related prognostic indicators in HCC. Tumor tissues exhibited a global increase in m5C sites abundance, with differential modifications enriched on chromosomes 1–3. Genes harboring m5C modifications were significantly enriched in immune and inflammatory pathways, suggesting a potential role for this epitranscriptomic mark in remodeling the tumor immune microenvironment. Consistent upregulation of m5C regulators, including NSUN family members and ALYREF , at both gene and isoform levels, correlated with increased methylation activity. Elevated m5C coupled with decreased CES3 expression were associated with poorer overall survival. Additionally, TMEM234 showed prognostic significance despite unchanged bulk expression in public datasets. m5C modifications are globally altered in HBV‐negative HCC and may contribute to post‐transcriptional regulation and aberrant expression. These findings highlight the potential of m5C as both a prognostic biomarker and a therapeutic target in HBV‐negative HCC.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularLiver Neoplasms5-MethylcytosineNanopore SequencingHumansRNA MethylationHepatitis B virusPrognosisGene Expression Regulation, NeoplasticEpitranscriptomeFemaleMaleBiomarkers, TumorEpitranscriptomicsEpigenesis, GeneticMiddle AgedTranscriptomeGene Expression Profiling

Author keywords

RNA 5‐methylcytidine methylationhepatocellular carcinomananopore sequencing

Substances

5-MethylcytosineBiomarkers, Tumor

Authors and institutions

  • Department of General Surgery, Department of Hepato-bilio-pancreatic Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • Clinical Biobank, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Bei…
  • School of Life Science, Beijing Institute of Technology, Beijing, China.
  • Department of Scientific Research and Education, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Coll…
  • St. John's Northwestern Academy, Delafield, Wisconsin, USA.

ORCID profiles: Tianhan Sun

Funding

  • Beijing Natural Science Foundation
  • CAMS Innovation Fund for Medical Sciences (CIFMS)
  • National Key Research and Development Program of China
  • National High Level Hospital Clinical Research
  • Natural Science Foundation of Beijing Municipality
  • National Basic Research Program of China

Cite

APA

Sun, T., Zhou, L., Li, X., Xiao, R., Sun, G., Zhang, L., Li, Y., Huang, W., Li, Y., Kuai, L., Luo, X., Cui, H., & Chen, M. (2026). The 5‐Methylcytosine RNA Modification in Hepatitis B Virus‐Negative Hepatocellular Carcinoma: Insights From Long‐Read Nanopore Sequencing. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70080

Vancouver

Sun T, Zhou L, Li X, Xiao R, Sun G, Zhang L, et al. The 5‐Methylcytosine RNA Modification in Hepatitis B Virus‐Negative Hepatocellular Carcinoma: Insights From Long‐Read Nanopore Sequencing. Molecular Carcinogenesis. 2026. doi:10.1002/mc.70080

BibTeX
@article{Sun2026,
  author = {Sun, Tianhan and Zhou, Liying and Li, XiaoQing and Xiao, Ryan and Sun, Gaoyuan and Zhang, Lili and Li, Yifei and Huang, Wei and Li, Yayu and Kuai, Lu and Luo, Xuanmei and Cui, Hongyuan and Chen, Meng},
  title = {The 5‐Methylcytosine RNA Modification in Hepatitis B Virus‐Negative Hepatocellular Carcinoma: Insights From Long‐Read Nanopore Sequencing},
  journal = {Molecular Carcinogenesis},
  year = {2026},
  doi = {10.1002/mc.70080}
}
Start for free →